Yu.A. Kondakova

Yu.A. Kondakova

Auto-generated profile, based on publicly available information

Yu.A. Kondakova

State budgetary healthcare institution of the Novosibirsk region “City Children’s Clinical Hospital of Emergency Medical Care

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2024 in PULMONOLOGIYA
Verified
Journal Article
Open access
PDF file
VSV. V. Shadrina
V. V. Shadrina
EZElena Zhekaite
Elena Zhekaite
AVAnna Voronkova
Anna Voronkova
VSVictoria Sherman
Victoria Sherman
YKYu. A. Kondakova
Yu. A. Kondakova
EKElena Kondatyeva
Elena Kondatyeva
Mannitol for inhalation is recommended for the treatment of cystic fibrosis in children over 6 years of age and adults. Because of the risk of bronchospasm, a challenge test to assess the drug tolerability should be performed prior to prescribing inhalation mannitol. Aim. Tо evaluate the tolerability of the first dose of inhaled mannitol in children with cystic fibrosis. Methods. The mannitol challenge test (according to the instructions for use of the Bronchitol (inhaled mannitol), Pharmaxis Ltd, Australia) was assessed in 81 children aged 6 to 18 years (11.6 ± 3.2 years). The patients were observed in the centers of the Novosibirsk region, the Moscow region, and the Perm region. The patient’s general state, forced expiratory volume in the first second (FEV1), and SpO2 were monitored. Results. Baseline FEV1 data in patients ranged from 30 % to 146 % (87.8 ± 25.7%), and SpO2 was 94 – 99% (97.7 ± 1.3%). 73 (90.1%) patients passed the test. In 8 (9.9%) patients, the following symptoms were observed: bronchospasm (6), laryngospasm (1), and vomiting (1). Bronchial obstruction was treated by inhalation of a bronchodilator, and the children were under observation until the restoration of FEV1. In patients who passed the test, FEV1 ranged from 33 to 149 % (85.4 ± 24.5%), and SpO2 spanned from 95 to 99% (96.7 ± 1.7%). The children who did not pass the test were monitored. One patient passed the test later when targeted therapy was added. Two children did not tolerate other mucolytic drugs (one child – NaCl solution in various dilutions, and the second patient suffering from asthma – dornase alfa). During follow-up, one patient was diagnosed with allergic bronchopulmonary aspergillosis at 12 years of age and with asthma at 13 years of age, which may have influenced the decrease in mannitol tolerability through formation of bronchial hyperreactivity. Thus, true adverse drug reaction in the form of bronchospasm occurred in three children out of 81 (3.7%). Conclusion. 90.1% of patients passed the inhalation mannitol challenge test, and 9.9% of patients did not pass the test. Analysis of adverse drug reactions revealed that only 3.7% of patients experienced true adverse reactions in the form of bronchospasm. During the test, patients were taught the correct technique for inhaling the drug. All the supplies to relieve bronchospasm should be readily available during the test.

22 April 2019 in Siberian Medical Review
Verified
Journal Article
Closed access
MHMunicipal Children’s Clinical Emergency Hospital
Municipal Children’s Clinical Emergency Hospital
YKYu.A. Kondakova
Yu.A. Kondakova
AVAnna Voronkova
Anna Voronkova
MCMedical Genetic Research Center
Medical Genetic Research Center
SZS.K. Zyryanov
S.K. Zyryanov
IBI.B. Bondareva
I.B. Bondareva

23 December 2020 in PULMONOLOGIYA
Verified
Journal Article
Closed access
PDF file
EKElena Kondatyeva
Elena Kondatyeva
YKYu. A. Kondakova
Yu. A. Kondakova
LNL. P. Nazarenko
L. P. Nazarenko
SKS. A. Krasovskiy
S. A. Krasovskiy
TST. I. Safonova
T. I. Safonova
IKI. A. Kirshina
I. A. Kirshina
Клинико-эпидемиологические характеристики больных муковисцидозом, проживающих на территории Сибирского федерального округа, по данным национального регистра (2017)

11 April 2021 in PULMONOLOGIYA
Verified
Journal Article
Closed access
PDF file
EKElena Kondatyeva
Elena Kondatyeva
AVAnna Voronkova
Anna Voronkova
STS. V. Trishina
S. V. Trishina
NSN. S. Snetkova
N. S. Snetkova
TST. I. Safonova
T. I. Safonova
EVE. V. Vodovozova
E. V. Vodovozova
Study of efficacy, safety, and patient satisfaction with inhaled tobramycin (Tobramycin-Gobbi) in children with cystic fibrosis and pseudomonas infectionAim of the study was to assess efficacy and safety of Tobramycin-Gobbi in CF, as well as the patients’ satisfaction with the treatment.Methods. 35 children from 6 to 18 years with CF were enrolled in this non-interventional prospective cohort multicenter study. All children had P. aeruginosa in the respiratory tract (newly diagnosed, recurrent, or chronic infection). The children received inhalation treatment with Tobramycin-Gobbi in the following cycles: 28-day treatment/28-day break, for 6 months. The studied parameters included respiratory function, bacterial cultures of the respiratory tract with a bacterial count, growth and body weight, antibiotic therapy for the respiratory episodes. The children and parents filled in a questionnaire “Treatment satisfaction assessment” and assessed their state of health on the visual-analog scale before and after each treatment cycle.Results. P. aeruginosa was eradicated in 17.7% of cases (6 patients, including 2 newly diagnosed, 3 recurrent infections, and 1 chronic infection), reduced bacterial count, decreased number of courses of antibiotic therapy, improvement of FEV1. Adverse reactions were reported by one patient.Conclusion. The efficacy, safety, and tolerability of Tobramicine Gobbi were confirmed in the patients with newly diagnosed, recurrent, and chronic infection caused by P. aeruginosa.

22 April 2019 in Siberian Medical Review
Verified
Journal Article
Closed access
SKS.V. Kostyuk
S.V. Kostyuk
RGResearch Center for Medical Genetic
Research Center for Medical Genetic
MKM.S. Kon’kova
M.S. Kon’kova
EEElizaveta Ershova
Elizaveta Ershova
YKYu.A. Kondakova
Yu.A. Kondakova
PWPerm State Medical University named after Academician Ye.A. Wagner
Perm State Medical University named after Academician Ye.A. Wagner

12 August 2019 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
EKE.I. Kondratieva
E.I. Kondratieva
YKYu.A. Kondakova
Yu.A. Kondakova
SZS.K. Zyryanov
S.K. Zyryanov
IBI.B. Bondareva
I.B. Bondareva
AVAnna Voronkova
Anna Voronkova
NHNovosibirsk Novosibirsk City Children'S Clinical Emergency Hospital
Novosibirsk Novosibirsk City Children'S Clinical Emergency Hospital
Облако Mail.Ru - это ваше персональное надежное хранилище в интернете. Все нужные файлы всегда под рукой, доступны в любой точке мира с компьютера или смартфона.